期刊文献+

小梁切除术联合甲钴胺治疗晚期青光眼的疗效观察 被引量:2

CLINICAL EFFECTS OF TRABECULECTOMY COMBINED WITH MECOBALAMIN IN TREATING LATE GLAUCOMA
下载PDF
导出
摘要 目的:探讨小梁切除术联合甲钴胺治疗晚期青光眼的疗效。方法:选择46例晚期青光眼行小梁切除术,术中应用可拆除调整缝线,术后联合应用口服甲钴胺糖衣片0.5g tid,连续3~6个月。结果:术前眼压平均值为38.97+2.91mmHg,术后眼压平均值为14.41+2.17 mmHg。术后2周视力提高大于两行10眼(21.74%),视力提高小于两行20眼(43.48%),不提高14眼(30.43%),减退2眼(4.34%),追踪观察6~24个月,无视力丧失。视野改善8眼(17.39%),视野不变34眼(73.91%),视野缩窄4眼(8.70%)。结论:晚期青光眼通过小梁切除术,联合视神经保护剂的应用,可有效控制眼压,避免视力过早丧失。 Objective:To investigate the effects of trabeculectomy combined with mecobalamon in treating late glaucoma.Methods:46 patients with late glaucoma were treated by trabeculectomy.Adjustable suture was applied.All patients received mecobalamin therapy after operation for 3 to 6 months.Results:Mean intraocular pressure(IOP) before and after operation was 38.97±2.91mmHg,and 14.41±2.17mmHg.In terms of vision change 2 weeks after operation: 10 eyes(21.74%) improved by more than two lines,20 eyes(43.48%) improved by less than two lines,14 eyes(30.43%) showed no improvement,and 2 eyes(4.34%) decreased.All 46 patients were followed-up for 6 to 24 monthes,no loss of vision ever found.In terms of visual field after operation:8 eyes(17.39%) improved,34 eyes(73.91%) had no change,and 4 eyes(8.70%) worsened.Conclusion:For late glaucoma,trabeculectormy combined with neuroprotective agents can effectively control IOP and slow down the loss of visual function.
出处 《泸州医学院学报》 2011年第4期404-405,共2页 Journal of Luzhou Medical College
关键词 青光眼 小梁切除术 甲钴胺 Glaucoma Trabeculectomy Mecobalamin
  • 相关文献

参考文献3

二级参考文献19

  • 1葛坚,郭彦.青光眼视神经损伤与视神经保护[J].食品与药品,2005,7(05A):17-23. 被引量:20
  • 2NAKAZAWA T, TSURUMIZU T, HIRANO S, et al, Phospholigid syntesis and methy lcobalam in nerve regeneration [ J ]. Peripheral Neuropathy, 1983, 20(22) : 435 -439.
  • 3[2]Hoyng PF,Van Beek LM. Pharmacological therapy for glaucoma [J]. Drugs ,2000,59:411 - 434.
  • 4[3]Patelska B, Greenfield DS, Liebmann JM, et al. Latanoprost for uncontrolled glaucoma in a compassionate case protocol[J ]. Am J Ophthalmol, 1997,124:279 - 286.
  • 5[4]Chiou GCY. Effects of NO on eye diseases and their treatment [J ]. J Ocular Pharmacol Ther, 2001,in press.
  • 6[5]Neufeld AH, Sawada A, Becker B. Inhibition of NOS-2 by aminoguanine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma[J ]. Proc Natl Acad Sci USA,1999,96: 9944 - 9948.
  • 7[6]Kaufman PC. NOS and neurodegeneration/neuroprotection [ J ].Proc Natl Acad Sci USA, 1999,96: 9455 - 9456.
  • 8[7]Dawson VL, Dawson TM. Physiological and toxicological action of NO in the CNS[ A]. In:Nitric oxide, biochemistry, molecularbiology and therapeutic implications[ M]. New York: Acadenfic Press, 1995. 323 - 342.
  • 9[8]Szabo C,Theimermann C. Regulation of the inducible isoform of NOS[ A]. In: Ignarro L, Murad, Eds. Nitric Oxide, biochemistry,molecular biology and therapeutic implications[ M ]. New York:Academic Press, 1995.113- 153.
  • 10[9]lgnarro LJ. NO as a communication signal in vascular and neuronal cells[ A]. In: Lancaster J, Ed. Nitric oxide, principles and ctions[ M ]. New York: Academic Press, 1996. 1 1 1 - 137.

共引文献14

同被引文献25

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部